ÐǺ£ÆåÅÆ
Transforming the treatment of cancer and other serious diseases
Antibody Science
Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Our Impact
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Investors
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Stock Information
News & Insights
ÐǺ£ÆåÅÆ
Antibody Science
Our Impact
Investors
News & Insights
ÐǺ£ÆåÅÆ Regional Sites
Our History
A history of accomplishments rooted in science
Our history has been powered by a dedication to antibody-based therapeutics. It is this same spirit that will guide us into the future.
2024
2024
ÐǺ£ÆåÅÆ celebrates 25th anniversary
Fourth regulatory approval for a therapy created using ÐǺ£ÆåÅÆ’s proprietary DuoBody® bispecific technology platform
April 27, 2023
ÐǺ£ÆåÅÆ enters partnership with argenx as a steppingstone to broaden its vision beyond oncology and into immunology and inflammation
May 19, 2023
First regulatory approval in US for EPKINLY®* (epcoritamab) and third regulatory approval for a therapy using ÐǺ£ÆåÅÆ’s DuoBody® technology platform.
*See local prescribing information for full indication and safety information. EPKINLY is being co-developed and copromoted by ÐǺ£ÆåÅÆ and AbbVie
Second regulatory approval for a therapy created using ÐǺ£ÆåÅÆ’s proprietary DuoBody® bispecific technology platform
ÐǺ£ÆåÅÆ submits regulatory applications for epcoritamab in the US and Japan; ÐǺ£ÆåÅÆ’s partner AbbVie files for approval in EU
Epcoritamab receives US FDA orphan-drug designation
ÐǺ£ÆåÅÆ’s 2030 Vision unveiled
Regulatory approval in the US for ÐǺ£ÆåÅÆ’s first therapy, TIVDAK®* (tisotumab vedotin)
*See local prescribing information for full indication and safety information. TIVDAK is being co-developed and co-promoted by ÐǺ£ÆåÅÆ and Pfizer.
First regulatory approval for a therapy created using ÐǺ£ÆåÅÆ’s proprietary DuoBody® bispecific technology platform
First regulatory approval in US for Kesimpta®* (ofatumumab)
*See local prescribing information for full indication and safety information. KESIMPTA is commercialized by Novartis.
May
First regulatory approvals in US and Europe for subcutaneous formulation of daratumumab*
*See local prescribing information for full indication and safety information. DARZALEX FASPRO/DARZALEX SC is developed & commercialized by Janssen.
First regulatory approval in US for TEPEZZA®* (teprotumumab)
*See local prescribing information for full indication and safety information. TEPEZZA is developed and commercialized by Amgen.
ÐǺ£ÆåÅÆ and AbbVie enter into broad oncology collaboration
ÐǺ£ÆåÅÆ celebrates 20th anniversary
ÐǺ£ÆåÅÆ becomes a dual-listed company with shares traded on Nasdaq Copenhagen and Nasdaq Global Select Market in the US in landmark IPO
ÐǺ£ÆåÅÆ signs agreement with Janssen for next-generation CD38 Antibody, HexaBody-CD38
ÐǺ£ÆåÅÆ introduces HexElect® technology platform
Seagen (now Pfizer) exercises option to co-develop and co-commercialize tisotumab vedotin
First regulatory approval in Japan for DARZALEX®* (daratumumab)
*See local prescribing information for full indication and safety information. DARZALEX is developed and commercialized by Janssen
First regulatory approval in Europe for DARZALEX®* (daratumumab)
*See local prescribing information for full indication and safety information. DARZALEX is developed and commercialized by Janssen.
ÐǺ£ÆåÅÆ enters commercial agreements with Novo Nordisk and BioNTech for DuoBody® technology
First regulatory approval in the US for DARZALEX®* (daratumumab)
*See local prescribing information for full indication and safety information. DARZALEX is developed and commercialized by Janssen
ÐǺ£ÆåÅÆ raises DKK 998 million in international private placement

Daratumumab receives breakthrough therapy designation from the US FDA
ÐǺ£ÆåÅÆ enters collaboration with Janssen for daratumumab
ÐǺ£ÆåÅÆ enters DuoBody® platform collaboration with Janssen
ÐǺ£ÆåÅÆ introduces the HexaBody® technology platform
ÐǺ£ÆåÅÆ introduces the DuoBody® technology platform
Jan van de Winkel becomes CEO
ÐǺ£ÆåÅÆ enters collaborations with Lundbeck and Seagen (acquired by Pfizer)
Arzerra®* (ofatumumab) receives regulatory approval in the US
*See local prescribing information for full indication and safety information. Commercialized by Novartis. Rights to ofatumumab transferred from GSK to Novartis.
ÐǺ£ÆåÅÆ and GSK sign a co-development and commercialization agreement for ofatumumab
ÐǺ£ÆåÅÆ selects daratumumab as CD38 antibody candidate
ÐǺ£ÆåÅÆ enters its first major partnership, an antibody development collaboration with Roche
IPO in Copenhagen raises DKK 1.56 billion, a European biotech record
ÐǺ£ÆåÅÆ founded in Copenhagen, Denmark
ÐǺ£ÆåÅÆ celebrates 25th anniversary
Fourth regulatory approval for a therapy created using ÐǺ£ÆåÅÆ’s proprietary DuoBody® bispecific technology platform
April 27, 2023
ÐǺ£ÆåÅÆ enters partnership with argenx as a steppingstone to broaden its vision beyond oncology and into immunology and inflammation
May 19, 2023
First regulatory approval in US for EPKINLY®* (epcoritamab) and third regulatory approval for a therapy using ÐǺ£ÆåÅÆ’s DuoBody® technology platform.
*See local prescribing information for full indication and safety information. EPKINLY is being co-developed and copromoted by ÐǺ£ÆåÅÆ and AbbVie
Second regulatory approval for a therapy created using ÐǺ£ÆåÅÆ’s proprietary DuoBody® bispecific technology platform
ÐǺ£ÆåÅÆ submits regulatory applications for epcoritamab in the US and Japan; ÐǺ£ÆåÅÆ’s partner AbbVie files for approval in EU
Epcoritamab receives US FDA orphan-drug designation
ÐǺ£ÆåÅÆ’s 2030 Vision unveiled
Regulatory approval in the US for ÐǺ£ÆåÅÆ’s first therapy, TIVDAK®* (tisotumab vedotin)
*See local prescribing information for full indication and safety information. TIVDAK is being co-developed and co-promoted by ÐǺ£ÆåÅÆ and Pfizer.
First regulatory approval for a therapy created using ÐǺ£ÆåÅÆ’s proprietary DuoBody® bispecific technology platform
First regulatory approval in US for Kesimpta®* (ofatumumab)
*See local prescribing information for full indication and safety information. KESIMPTA is commercialized by Novartis.
May
First regulatory approvals in US and Europe for subcutaneous formulation of daratumumab*
*See local prescribing information for full indication and safety information. DARZALEX FASPRO/DARZALEX SC is developed & commercialized by Janssen.
First regulatory approval in US for TEPEZZA®* (teprotumumab)
*See local prescribing information for full indication and safety information. TEPEZZA is developed and commercialized by Amgen.
ÐǺ£ÆåÅÆ and AbbVie enter into broad oncology collaboration
ÐǺ£ÆåÅÆ celebrates 20th anniversary
ÐǺ£ÆåÅÆ becomes a dual-listed company with shares traded on Nasdaq Copenhagen and Nasdaq Global Select Market in the US in landmark IPO
ÐǺ£ÆåÅÆ signs agreement with Janssen for next-generation CD38 Antibody, HexaBody-CD38
ÐǺ£ÆåÅÆ introduces HexElect® technology platform
Seagen (now Pfizer) exercises option to co-develop and co-commercialize tisotumab vedotin
First regulatory approval in Japan for DARZALEX®* (daratumumab)
*See local prescribing information for full indication and safety information. DARZALEX is developed and commercialized by Janssen
First regulatory approval in Europe for DARZALEX®* (daratumumab)
*See local prescribing information for full indication and safety information. DARZALEX is developed and commercialized by Janssen.
ÐǺ£ÆåÅÆ enters commercial agreements with Novo Nordisk and BioNTech for DuoBody® technology
First regulatory approval in the US for DARZALEX®* (daratumumab)
*See local prescribing information for full indication and safety information. DARZALEX is developed and commercialized by Janssen
ÐǺ£ÆåÅÆ raises DKK 998 million in international private placement

Daratumumab receives breakthrough therapy designation from the US FDA
ÐǺ£ÆåÅÆ enters collaboration with Janssen for daratumumab
ÐǺ£ÆåÅÆ enters DuoBody® platform collaboration with Janssen
ÐǺ£ÆåÅÆ introduces the HexaBody® technology platform
ÐǺ£ÆåÅÆ introduces the DuoBody® technology platform
Jan van de Winkel becomes CEO
ÐǺ£ÆåÅÆ enters collaborations with Lundbeck and Seagen (acquired by Pfizer)
Arzerra®* (ofatumumab) receives regulatory approval in the US
*See local prescribing information for full indication and safety information. Commercialized by Novartis. Rights to ofatumumab transferred from GSK to Novartis.
ÐǺ£ÆåÅÆ and GSK sign a co-development and commercialization agreement for ofatumumab
ÐǺ£ÆåÅÆ selects daratumumab as CD38 antibody candidate
ÐǺ£ÆåÅÆ enters its first major partnership, an antibody development collaboration with Roche
IPO in Copenhagen raises DKK 1.56 billion, a European biotech record
ÐǺ£ÆåÅÆ founded in Copenhagen, Denmark